Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933306 | 1.00 | DGAT1 (0.33) | DGAT1HPGDTAAR1NR1H4PDCD1LG2 | |
| SCHEMBL15368135 | 0.77 | DGAT1 (0.40) | DGAT1TAAR1 | |
| SCHEMBL1888700 | 0.77 | L3MBTL1 (0.39) | DGAT1HPGD | |
| SCHEMBL16105980 | 0.76 | TAAR1 (0.36) | DGAT1TAAR1 | |
| SCHEMBL16105981 | 0.76 | TAAR1 (0.36) | DGAT1TAAR1 | |
| Hydrochloric Acid SCHEMBL2813401 | 0.75 | TAAR1 (0.35) | DGAT1TAAR1 | |
| SCHEMBL20055477 | 0.71 | KLKB1 (0.36) | DGAT1TAAR1 | |
| SCHEMBL1074616 | 0.71 | CYP3A4 (0.46) | KCNH2 | |
| Hydrochloric Acid SCHEMBL535924 | 0.67 | L3MBTL1 (0.34) | DGAT1TAAR1 | |
| SCHEMBL16144076 | 0.66 | GRM1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | DGAT1 1994/4885HPGD 1841/4885TAAR1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.